July 24th 2024
Oncology nurses can utilize risk assessment to predict patients at increased risk for cisplatin-induced acute kidney injury.
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Savolitinib Plus Durvalumab Induces High Response Rates in MET-Driven Papillary Renal Cancer
March 4th 2023A combination of immune checkpoint inhibitor and MET-targeted therapy led to high responses in patients with MET-driven papillary renal cancer, although the regimen missed its primary end point.
Talazoparib/Enzalutamide Improves Imaging-Based PFS in Metastatic CRPC, Regardless of HRR Status
February 17th 2023At a median follow-up of 24.9 months, imaging-based progression-free survival was not reached among patients with metastatic castration-resistant prostate cancer who had received talazoparib plus enzalutamide.
Nivolumab/Ipilimumab May Be Most Effective mRCC Treatment, Sunitinib Most Cost-Effective
January 18th 2023A decision model with a 10-year time horizon found that nivolumab plus ipilimumab was the most effective combination for patients with metastatic renal cell carcinoma, but sunitinib was the most cost-effective approach.
Neoadjuvant Split-Dose Chemotherapy Represents Potential New Standard of Care for High-Risk UTUC
January 13th 2023Neoadjuvant treatment with gemcitabine and split-dose cisplatin followed by surgical resection and lymph node dissection proved to be effective and well-tolerated for patients with high-risk upper tract urothelial carcinoma.
Rogaratinib May Be Effective for Patients With Bladder Cancer and FGFR3 DNA Alterations
November 14th 2022Rogaratinib did not display a significant benefit over chemotherapy in patients with FGFR mutated bladder cancer, but the targeted treatment did generate encouraging responses among those with FGFR3 DNA alterations.
Adjuvant RCC Therapy Remains a Challenge as Treatment Landscape Continues to Evolve
November 3rd 2022Nancy Moldawer, RN, MSN, cochair of the Kidney Cancer Association's Clinical Advisory Board, speaks to unfolding data in the renal cell carcinoma space and the challenges in providing adjuvant therapy to this patient population.
Adding Cediranib to Olaparib Increases Treatment Efficacy, But Raises Toxicity Concerns, in mCRPC
October 29th 2022A regimen of cediranib and olaparib improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer compared with olaparib monotherapy. However, the rate of dose reductions was doubled with the combination.